8legs: American society of clinical oncology (asco)

#1 out of 198.55%

Daily pill can double survival time for world’s deadliest cancer, trial shows

A new trial shows daraxonrasib can double survival in advanced pancreatic cancer, with 13.2 months vs 6.6–6.7 months.
Experts call the results landscape-changing and a potential gamechanger for pancreatic cancer treatment.
The drug targets Kras, a protein driving most pancreatic cancers, turning off the cancer growth signal.
The trial involved 500 patients with metastatic pancreatic cancer and was presented at ASCO in Chicago.
Researchers hail the study as a home run and a grand slam for cancer treatment advances.
Daraxonrasib is a Ras inhibitor classified as Ras(On) multi-selective, effective across Kras variants.
Health groups praised the results as a major breakthrough that could expand treatment options.
The Guardian notes leaders hope Ras-targeting drugs may also benefit lung and colon cancers.
The study was conducted by researchers at the Dana-Farber Cancer Institute and presented at ASCO.
Participants had metastatic pancreatic ductal adenocarcinoma and tolerated the new drug with fewer side effects.

Vote 0